|
Adult Diffuse Large B-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).
|
22575864 |
2012 |
|
Benign melanocytic nevus
|
|
0.010 |
GeneticVariation
|
BEFREE |
Nine cases presented concomitant BRAF and NRAS mutations, including one case in which both the melanoma and the adjacent naevus harboured V600E and Q61K double mutations.
|
25857817 |
2015 |
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, in human non-small-cell lung carcinoma H1299 cells harboring N-Ras Q61K oncogenic mutation and p53 deletion, overexpression of Nm23H1 did not affect tumorigenesis in nude mice assays, while overexpression of Nm23H2 enhanced tumor growth with elevated expression of the c-Myc proto-oncogene.
|
25748386 |
2015 |
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
|
Congenital naevus
|
|
0.010 |
GeneticVariation
|
BEFREE |
A mutation in the Cdon gene potentiates congenital nevus development mediated by NRAS(Q61K).
|
27155367 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H).
|
22575864 |
2012 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Overall, 13 cases (46%) harbored RAS mutations, including seven (25%) with NRAS mutations (p.Gln61Arg) and six (21%) with HRAS mutations (five had p.Gln61Arg and one had a p.Gln61Lys substitution).No PE/WC FVPTCs had BRAF mutations.
|
23477374 |
2013 |
|
GIANT PIGMENTED HAIRY NEVUS
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.
|
23392294 |
2013 |
|
GIANT PIGMENTED HAIRY NEVUS
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.
|
18633438 |
2009 |
|
Histiocytosis, Langerhans-Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
In seven out of 11 NRAS(Q61K) (/R)-mutated pulmonary LCH lesions, BRAF(V600) (E) mutations were also present.
|
27076591 |
2016 |
|
Lymphoma, T-Cell, Cutaneous
|
|
0.010 |
GeneticVariation
|
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show that the human sarcoma cell line HT1080 harbors both NRAS(Q61K) and RAC1(N92I) mutant proteins.
|
23382236 |
2013 |
|
Melanocytic nevus
|
|
0.010 |
GeneticVariation
|
BEFREE |
Nine cases presented concomitant BRAF and NRAS mutations, including one case in which both the melanoma and the adjacent naevus harboured V600E and Q61K double mutations.
|
25857817 |
2015 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
We generated mutant BRAF(V600E) melanoma cells that exhibit resistance to PLX4720, the tool compound for vemurafenib, that co-expressed mutant (Q61K) NRAS.
|
23076151 |
2012 |
|
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
|
22761467 |
2012 |
|
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
In summary, this report indicates that N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression, suggesting that Bim is a possible treatment target for overriding melanoma's inherent defenses against cell death.
|
18668139 |
2009 |
|
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
|
melanoma
|
|
0.780 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
melanoma
|
|
0.780 |
GeneticVariation
|
BEFREE |
Strikingly, the administration of BI-69A11 inhibited melanoma development in genetically modified mice bearing an inducible form of activated Nras and a deletion of the Ink4a gene (Nras((Q61K)) ::Ink4a(-/-) ).
|
23035722 |
2013 |